VIPDOMET 12.5/1000; 12.5 mg alogliptin (as benzoate) / 1000 mg metformin hydrochloride film-coated tablets blister pack

Country: Ástralía

Tungumál: enska

Heimild: Department of Health (Therapeutic Goods Administration)

Virkt innihaldsefni:

metformin hydrochloride, Quantity: 1000 mg; alogliptin benzoate, Quantity: 17 mg (Equivalent: alogliptin, Qty 12.5 mg)

Fáanlegur frá:

Takeda Pharmaceuticals Australia Pty Ltd

INN (Alþjóðlegt nafn):

Alogliptin benzoate,Metformin hydrochloride

Lyfjaform:

Tablet, film coated

Samsetning:

Excipient Ingredients: mannitol; purified talc; iron oxide yellow; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; crospovidone; hypromellose

Stjórnsýsluleið:

Oral

Einingar í pakka:

120, 112, 180, 56, 60, 14, 10, 196, 28, 98, 200, 20

Gerð lyfseðils:

(S4) Prescription Only Medicine

Ábendingar:

VIPDOMET is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,VIPDOMET can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Vörulýsing:

Visual Identification: Pale yellow, oblong, biconvex, film-coated tablets with 12.5/1000 debossed on one side and 322M debossed on the other side.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Leyfisstaða:

Registered

Leyfisdagur:

2013-10-22